{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T13:18:05Z","timestamp":1788787085364,"version":"build-2803163510"},"reference-count":166,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T00:00:00Z","timestamp":1761436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023731","name":"Consejer\u00eda de Salud y Consumo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["PI-0121-2024"],"award-info":[{"award-number":["PI-0121-2024"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023731","name":"Consejer\u00eda de Salud y Consumo, Junta de Andaluc\u00eda","doi-asserted-by":"publisher","award":["SEOM-GSK 2024"],"award-info":[{"award-number":["SEOM-GSK 2024"]}],"id":[{"id":"10.13039\/501100023731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006301","name":"Center for International Business Education and Research, University of Illinois at Urbana-Champaign","doi-asserted-by":"publisher","award":["CB16\/12\/00275"],"award-info":[{"award-number":["CB16\/12\/00275"]}],"id":[{"id":"10.13039\/100006301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008963","name":"Spanish Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008963","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ramon Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.biopha.2025.118719","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:54:29Z","timestamp":1761832469000},"page":"118719","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["DNA repair pathways in ovarian cancer: Implications for therapy and resistance"],"prefix":"10.1016","volume":"193","author":[{"given":"Isabel","family":"Miras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"V\u00e1zquez-Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purificaci\u00f3n","family":"Est\u00e9vez-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Mu\u00f1oz-Galv\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2025.118719_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2025.118719_bib2","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib3","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharm."},{"issue":"3","key":"10.1016\/j.biopha.2025.118719_bib4","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ygyno.2014.02.038","article-title":"\"Platinum resistant\" ovarian cancer: what is it, who to treat and how to measure benefit?","volume":"133","author":"Davis","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib5","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"issue":"7353","key":"10.1016\/j.biopha.2025.118719_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.biopha.2025.118719_bib7","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","article-title":"Investigators, Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Gonzalez-Martin","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.biopha.2025.118719_bib8","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.biopha.2025.118719_bib9","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus Bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib10","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118719_bib11","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-pathol-012414-040424","article-title":"DNA replication stress as a hallmark of cancer","volume":"10","author":"Macheret","year":"2015","journal-title":"Annu Rev. Pathol."},{"key":"10.1016\/j.biopha.2025.118719_bib12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1146\/annurev-biochem-013118-111315","article-title":"Eukaryotic base excision repair: new approaches shine light on mechanism","volume":"88","author":"Beard","year":"2019","journal-title":"Annu Rev. Biochem."},{"issue":"8","key":"10.1016\/j.biopha.2025.118719_bib13","doi-asserted-by":"crossref","first-page":"3811","DOI":"10.1093\/nar\/gkz120","article-title":"Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and regulatory proteins","volume":"47","author":"Alemasova","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib14","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s13048-018-0424-x","article-title":"DNA damage repair in ovarian cancer: unlocking the heterogeneity","volume":"11","author":"Gee","year":"2018","journal-title":"J. Ovarian Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004256","article-title":"DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers","volume":"10","author":"Osorio","year":"2014","journal-title":"PLoS Genet"},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib16","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1002\/1878-0261.12470","article-title":"A common SNP in the UNG gene decreases ovarian cancer risk in BRCA2 mutation carriers","volume":"13","author":"Baquero","year":"2019","journal-title":"Mol. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118719_bib17","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/IGC.0b013e3182a33f07","article-title":"Apurinic\/apyrimidinic endonuclease 1 polymorphisms are associated with ovarian cancer susceptibility in a Chinese population","volume":"23","author":"Zhang","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.biopha.2025.118719_bib18","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/109593","article-title":"An association between single nucleotide polymorphisms of Lys751Gln ERCC2 gene and ovarian cancer in Polish women","volume":"2015","author":"Michalska","year":"2015","journal-title":"Adv. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.3233\/CBM-150509","article-title":"Impact of RAD51 G135C and XRCC1 Arg399Gln polymorphisms on ovarian carcinoma risk in Serbian women","volume":"15","author":"Malisic","year":"2015","journal-title":"Cancer Biomark."},{"issue":"3","key":"10.1016\/j.biopha.2025.118719_bib20","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3233\/CBM-160643","article-title":"APE1 overexpression promotes the progression of ovarian cancer and serves as a potential therapeutic target","volume":"17","author":"Wen","year":"2016","journal-title":"Cancer Biomark."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib21","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/sj.bjc.6605541","article-title":"Human apurinic\/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers","volume":"102","author":"Al-Attar","year":"2010","journal-title":"Br. J. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2025.118719_bib22","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/ijc.27980","article-title":"Clinicopathological and functional significance of XRCC1 expression in ovarian cancer","volume":"132","author":"Abdel-Fatah","year":"2013","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.biopha.2025.118719_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.sbi.2023.102605","article-title":"At the core of nucleotide excision repair","volume":"80","author":"Kuper","year":"2023","journal-title":"Curr. Opin. Struct. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib24","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1097-2765(01)00281-7","article-title":"Sequential assembly of the nucleotide excision repair factors in vivo","volume":"8","author":"Volker","year":"2001","journal-title":"Mol. Cell"},{"issue":"18","key":"10.1016\/j.biopha.2025.118719_bib25","doi-asserted-by":"crossref","first-page":"19074","DOI":"10.1074\/jbc.M312611200","article-title":"Ordered conformational changes in damaged DNA induced by nucleotide excision repair factors","volume":"279","author":"Tapias","year":"2004","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib26","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.molcel.2007.03.009","article-title":"Distinct roles for the XPB\/p52 and XPD\/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair","volume":"26","author":"Coin","year":"2007","journal-title":"Mol. Cell"},{"issue":"22","key":"10.1016\/j.biopha.2025.118719_bib27","doi-asserted-by":"crossref","first-page":"4768","DOI":"10.1038\/sj.emboj.7601894","article-title":"Structural basis for the recruitment of ERCC1-XPF to nucleotide excision repair complexes by XPA","volume":"26","author":"Tsodikov","year":"2007","journal-title":"EMBO J."},{"issue":"8","key":"10.1016\/j.biopha.2025.118719_bib28","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/emboj.2009.49","article-title":"Coordination of dual incision and repair synthesis in human nucleotide excision repair","volume":"28","author":"Staresincic","year":"2009","journal-title":"EMBO J."},{"issue":"15","key":"10.1016\/j.biopha.2025.118719_bib29","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.1021\/bi00015a012","article-title":"Nucleotide excision repair DNA synthesis by DNA polymerase epsilon in the presence of PCNA, RFC, and RPA","volume":"34","author":"Shivji","year":"1995","journal-title":"Biochemistry"},{"issue":"11","key":"10.1016\/j.biopha.2025.118719_bib30","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1002\/cncr.21031","article-title":"Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma","volume":"103","author":"Stevens","year":"2005","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib31","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/iji.12484","article-title":"Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: a study in Chinese cohort","volume":"47","author":"Bao","year":"2020","journal-title":"Int. J. Immunogenet."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib32","article-title":"Association of expression of p53, livin, ERCC1, BRCA1 and PARP1 in epithelial ovarian cancer tissue with drug resistance and prognosis","volume":"216","author":"Zhang","year":"2020","journal-title":"Pathol. Res. Pr."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib33","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ygyno.2019.02.014","article-title":"ERCC1-XPF deficiency is a predictor of olaparib induced synthetic lethality and platinum sensitivity in epithelial ovarian cancers","volume":"153","author":"Mesquita","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"2A","key":"10.1016\/j.biopha.2025.118719_bib34","first-page":"645","article-title":"Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells","volume":"20","author":"Li","year":"2000","journal-title":"Anticancer Res."},{"issue":"7","key":"10.1016\/j.biopha.2025.118719_bib35","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.dnarep.2010.03.010","article-title":"Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells","volume":"9","author":"Arora","year":"2010","journal-title":"DNA Repair"},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib36","first-page":"1311","article-title":"Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines","volume":"63","author":"Selvakumaran","year":"2003","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.biopha.2025.118719_bib37","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1093\/jnci\/84.19.1512","article-title":"ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients","volume":"84","author":"Dabholkar","year":"1992","journal-title":"J. Natl. Cancer Inst."},{"issue":"11","key":"10.1016\/j.biopha.2025.118719_bib38","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/S0006-2952(00)00448-2","volume":"60","author":"Dabholkar","year":"2000","journal-title":"Biochem. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib39","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1172\/JCI117388","article-title":"Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy","volume":"94","author":"Dabholkar","year":"1994","journal-title":"J. Clin. Invest."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib40","first-page":"54","article-title":"Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients","volume":"10","author":"Khrunin","year":"2010","journal-title":"Pharm. J."},{"issue":"15","key":"10.1016\/j.biopha.2025.118719_bib41","first-page":"4229","article-title":"Trapping of DNA nucleotide excision repair factors by nonrepairable carcinogen adducts","volume":"62","author":"Buterin","year":"2002","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib42","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0921-8777(01)00095-7","article-title":"Cisplatin-induced apoptosis in 43-3B and 27-1 cells defective in nucleotide excision repair","volume":"486","author":"Dunkern","year":"2001","journal-title":"Mutat. Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib43","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1158\/1535-7163.MCT-07-0192","article-title":"Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers","volume":"7","author":"Stevens","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"7","key":"10.1016\/j.biopha.2025.118719_bib44","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1073\/pnas.1720355115","article-title":"ATR-Chk1 activation mitigates replication stress caused by mismatch repair-dependent processing of DNA damage","volume":"115","author":"Gupta","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118719_bib45","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1002\/cncr.11770","article-title":"Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma","volume":"98","author":"Geisler","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41571-018-0114-z","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pilie","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib47","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.yexcr.2014.07.004","article-title":"Exploiting DNA mismatch repair deficiency as a therapeutic strategy","volume":"329","author":"Guillotin","year":"2014","journal-title":"Exp. Cell Res."},{"issue":"16","key":"10.1016\/j.biopha.2025.118719_bib48","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.1074\/jbc.272.16.10917","article-title":"DNA polymerase delta is required for human mismatch repair in vitro","volume":"272","author":"Longley","year":"1997","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib49","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2005.06.027","article-title":"Reconstitution of 5\u2032-directed human mismatch repair in a purified system","volume":"122","author":"Zhang","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib50","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1074\/jbc.C200627200","article-title":"Transfer of the MSH2.MSH6 complex from proliferating cell nuclear antigen to mispaired bases in DNA","volume":"278","author":"Lau","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib51","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/S1097-2765(03)00428-3","article-title":"Mechanism of 5\u2032-directed excision in human mismatch repair","volume":"12","author":"Genschel","year":"2003","journal-title":"Mol. Cell"},{"key":"10.1016\/j.biopha.2025.118719_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/341723","article-title":"Hereditary ovarian cancer: not only BRCA 1 and 2 genes","author":"Toss","year":"2015","journal-title":"Biomed. Res. Int."},{"issue":"3","key":"10.1016\/j.biopha.2025.118719_bib53","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.ygyno.2019.12.031","article-title":"High homogeneity of MMR deficiency in ovarian cancer","volume":"156","author":"Fraune","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2025.118719_bib54","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1002\/ijc.25835","article-title":"Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America","volume":"129","author":"Murphy","year":"2011","journal-title":"Int. J. Cancer"},{"issue":"20","key":"10.1016\/j.biopha.2025.118719_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20205129","article-title":"Relationship between microsatellite instability, immune cells infiltration, and expression of immune checkpoint molecules in ovarian carcinoma: immunotherapeutic strategies for the future","volume":"20","author":"Yamashita","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib56","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10689-014-9728-1","article-title":"Distinct gene expression profiles in ovarian cancer linked to Lynch syndrome","volume":"13","author":"Jonsson","year":"2014","journal-title":"Fam. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib57","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1006\/gyno.2001.6279","article-title":"H. International Collaborative Group on, The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer","volume":"82","author":"Watson","year":"2001","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.biopha.2025.118719_bib58","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2015.12.005","article-title":"Ovarian cancer in Lynch syndrome; a systematic review","volume":"55","author":"Helder-Woolderink","year":"2016","journal-title":"Eur. J. Cancer"},{"issue":"3B","key":"10.1016\/j.biopha.2025.118719_bib59","first-page":"1449","article-title":"A change in promoter methylation of hMLH1 is a cause of acquired resistance to platinum-based chemotherapy in epithelial ovarian cancer","volume":"27","author":"Watanabe","year":"2007","journal-title":"Anticancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib60","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/s13148-019-0748-4","article-title":"Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer","volume":"11","author":"Tian","year":"2019","journal-title":"Clin. Epigenetics"},{"issue":"27","key":"10.1016\/j.biopha.2025.118719_bib61","doi-asserted-by":"crossref","first-page":"10512","DOI":"10.1074\/jbc.TM117.000374","article-title":"Nonhomologous DNA end-joining for repair of DNA double-strand breaks","volume":"293","author":"Pannunzio","year":"2018","journal-title":"J. Biol. Chem."},{"issue":"9","key":"10.1016\/j.biopha.2025.118719_bib62","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/nrm1202","article-title":"Mechanism and regulation of human non-homologous DNA end-joining","volume":"4","author":"Lieber","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"21","key":"10.1016\/j.biopha.2025.118719_bib63","doi-asserted-by":"crossref","first-page":"3413","DOI":"10.1038\/emboj.2009.276","article-title":"ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2","volume":"28","author":"Beucher","year":"2009","journal-title":"EMBO J."},{"issue":"9-10","key":"10.1016\/j.biopha.2025.118719_bib64","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.dnarep.2006.05.026","article-title":"Role of non-homologous end joining (NHEJ) in maintaining genomic integrity","volume":"5","author":"Burma","year":"2006","journal-title":"DNA Repair"},{"issue":"3","key":"10.1016\/j.biopha.2025.118719_bib65","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1269\/jrr.43.223","article-title":"Dimerization, translocation and localization of Ku70 and Ku80 proteins","volume":"43","author":"Koike","year":"2002","journal-title":"J. Radiat. Res"},{"issue":"10","key":"10.1016\/j.biopha.2025.118719_bib66","doi-asserted-by":"crossref","first-page":"5908","DOI":"10.1128\/MCB.18.10.5908","article-title":"Productive and nonproductive complexes of Ku and DNA-dependent protein kinase at DNA termini","volume":"18","author":"West","year":"1998","journal-title":"Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib67","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S0092-8674(02)00671-2","article-title":"Hairpin opening and overhang processing by an Artemis\/DNA-dependent protein kinase complex in nonhomologous end joining and V(D)J recombination","volume":"108","author":"Ma","year":"2002","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2025.118719_bib68","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41580-019-0152-0","article-title":"DNA double-strand break repair-pathway choice in somatic mammalian cells","volume":"20","author":"Scully","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"21","key":"10.1016\/j.biopha.2025.118719_bib69","doi-asserted-by":"crossref","first-page":"6170","DOI":"10.1093\/nar\/gkl840","article-title":"PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways","volume":"34","author":"Wang","year":"2006","journal-title":"Nucleic Acids Res."},{"issue":"18","key":"10.1016\/j.biopha.2025.118719_bib70","doi-asserted-by":"crossref","first-page":"6065","DOI":"10.1093\/nar\/gkq387","article-title":"The alternative end-joining pathway for repair of DNA double-strand breaks requires PARP1 but is not dependent upon microhomologies","volume":"38","author":"Mansour","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"3","key":"10.1016\/j.biopha.2025.118719_bib71","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/nsmb.2961","article-title":"Mechanism of microhomology-mediated end-joining promoted by human DNA polymerase theta","volume":"22","author":"Kent","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"7538","key":"10.1016\/j.biopha.2025.118719_bib72","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/nature14184","article-title":"Homologous-recombination-deficient tumours are dependent on Poltheta-mediated repair","volume":"518","author":"Ceccaldi","year":"2015","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trecan.2020.09.007","article-title":"Targeting the DNA repair enzyme polymerase theta in cancer therapy","volume":"7","author":"Schrempf","year":"2021","journal-title":"Trends Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2025.118719_bib74","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1158\/1078-0432.CCR-16-0564","article-title":"Ovarian cancers harbor defects in nonhomologous end joining resulting in resistance to Rucaparib","volume":"23","author":"McCormick","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2025.118719_bib75","doi-asserted-by":"crossref","first-page":"635","DOI":"10.3389\/fonc.2019.00635","article-title":"DNA-PK as an emerging therapeutic target in cancer","volume":"9","author":"Mohiuddin","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib76","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-54796-6","article-title":"Activity of M3814, an Oral DNA-PK inhibitor, in combination with topoisomerase II inhibitors in ovarian cancer models","volume":"9","author":"Wise","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.biopha.2025.118719_bib77","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1073\/pnas.1013715108","article-title":"Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells","volume":"108","author":"Patel","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149183","article-title":"Single gene prognostic biomarkers in ovarian cancer: a meta-analysis","volume":"11","author":"Willis","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib79","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1159\/000489418","article-title":"Downregulation of RIF1 enhances sensitivity to platinum-based chemotherapy in epithelial ovarian cancer (EOC) by regulating nucleotide excision repair (NER) pathway","volume":"46","author":"Liu","year":"2018","journal-title":"Cell Physiol. Biochem."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib80","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/0008-5472.CAN-14-2593","article-title":"A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance","volume":"75","author":"Ceccaldi","year":"2015","journal-title":"Cancer Res."},{"issue":"7538","key":"10.1016\/j.biopha.2025.118719_bib81","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nature14157","article-title":"Mammalian polymerase theta promotes alternative NHEJ and suppresses recombination","volume":"518","author":"Mateos-Gomez","year":"2015","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/genes13061101","article-title":"Synthetic lethality targeting poltheta","volume":"13","author":"Drzewiecka","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.biopha.2025.118719_bib83","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.gde.2021.06.009","article-title":"DNA helicases in homologous recombination repair","volume":"71","author":"Branzei","year":"2021","journal-title":"Curr. Opin. Genet Dev."},{"issue":"11","key":"10.1016\/j.biopha.2025.118719_bib84","doi-asserted-by":"crossref","first-page":"a012740","DOI":"10.1101\/cshperspect.a012740","article-title":"Repair of strand breaks by homologous recombination","volume":"5","author":"Jasin","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.biopha.2025.118719_bib85","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1146\/annurev-genet-051710-150955","article-title":"Regulation of homologous recombination in eukaryotes","volume":"44","author":"Heyer","year":"2010","journal-title":"Annu Rev. Genet"},{"issue":"7214","key":"10.1016\/j.biopha.2025.118719_bib86","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/nature07312","article-title":"Sae2, Exo1 and Sgs1 collaborate in DNA double-strand break processing","volume":"455","author":"Mimitou","year":"2008","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib87","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1101\/gad.2003811","article-title":"BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair","volume":"25","author":"Nimonkar","year":"2011","journal-title":"Genes Dev."},{"issue":"9","key":"10.1016\/j.biopha.2025.118719_bib88","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18091886","article-title":"The Role of PALB2 in the DNA Damage Response and Cancer Predisposition","volume":"18","author":"Nepomuceno","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2025.118719_bib89","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev.biochem.77.061306.125255","article-title":"Mechanism of eukaryotic homologous recombination","volume":"77","author":"San Filippo","year":"2008","journal-title":"Annu Rev. Biochem."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib90","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/nrm1127","article-title":"Molecular views of recombination proteins and their control","volume":"4","author":"West","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.biopha.2025.118719_bib91","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.dnarep.2018.08.021","article-title":"Mechanisms of PARP inhibitor sensitivity and resistance","volume":"71","author":"D'Andrea","year":"2018","journal-title":"DNA Repair"},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2020.e03841","article-title":"The dynamic landscape of BRCA1 reversion mutations from indel to SNV in a patient with ovarian cancer treated with PARP-inhibitors and immunotherapy","volume":"6","author":"Jacob","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.biopha.2025.118719_bib93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.dnarep.2019.06.005","article-title":"DNA damage response and repair in ovarian cancer: Potential targets for therapeutic strategies","volume":"80","author":"Mirza-Aghazadeh-Attari","year":"2019","journal-title":"DNA Repair"},{"issue":"3","key":"10.1016\/j.biopha.2025.118719_bib94","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-13-2287","article-title":"Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas","volume":"20","author":"Pennington","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib95","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Embrace, I. kConFab, N. Cancer Genome Atlas Research, Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.biopha.2025.118719_bib96","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1001\/jama.2011.1456","article-title":"Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer","volume":"306","author":"Yang","year":"2011","journal-title":"JAMA"},{"issue":"21","key":"10.1016\/j.biopha.2025.118719_bib97","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","article-title":"BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group","volume":"30","author":"Alsop","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2025.118719_bib98","first-page":"5329","article-title":"BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study","volume":"60","author":"Baldwin","year":"2000","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2025.118719_bib99","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1038\/sj.onc.1202509","article-title":"Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics","volume":"18","author":"Catteau","year":"1999","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.biopha.2025.118719_bib100","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ejca.2014.05.001","article-title":"BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD)","volume":"50","author":"Ruscito","year":"2014","journal-title":"Eur. J. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2025.118719_bib101","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10120487","article-title":"Role of BRCA mutations in cancer treatment with Poly(ADP-ribose) polymerase (PARP) inhibitors","volume":"10","author":"Faraoni","year":"2018","journal-title":"Cancers"},{"issue":"15","key":"10.1016\/j.biopha.2025.118719_bib102","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2009.25.1082","article-title":"Increased incidence of visceral metastases in scottish patients with BRCA1\/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype","volume":"28","author":"Gourley","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib103","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrm3805","article-title":"Mechanisms and principles of homology search during recombination","volume":"15","author":"Renkawitz","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib104","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41594-018-0075-z","article-title":"RPA and RAD51: fork reversal, fork protection, and genome stability","volume":"25","author":"Bhat","year":"2018","journal-title":"Nat. Struct. Mol. Biol."},{"issue":"26","key":"10.1016\/j.biopha.2025.118719_bib105","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.2015.61.2408","article-title":"Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population","volume":"33","author":"Song","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib106","doi-asserted-by":"crossref","DOI":"10.1038\/ng.2224","article-title":"Germline RAD51C mutations confer susceptibility to ovarian cancer","volume":"44","author":"Loveday","year":"2012","journal-title":"Nat. Genet"},{"issue":"16","key":"10.1016\/j.biopha.2025.118719_bib107","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1158\/0008-5472.CAN-17-0190","article-title":"Functionally null RAD51D missense mutation associates strongly with ovarian carcinoma","volume":"77","author":"Rivera","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2025.118719_bib108","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1038\/srep04026","article-title":"Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status","volume":"4","author":"Cunningham","year":"2014","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib109","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s10637-008-9208-2","article-title":"INNO-206, the (6-maleimidocaproyl hydrazone derivative of doxorubicin), shows superior antitumor efficacy compared to doxorubicin in different tumor xenograft models and in an orthotopic pancreas carcinoma model","volume":"28","author":"Graeser","year":"2010","journal-title":"Invest N. Drugs"},{"issue":"12","key":"10.1016\/j.biopha.2025.118719_bib110","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809172","article-title":"A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation","volume":"10","author":"Castroviejo-Bermejo","year":"2018","journal-title":"EMBO Mol. Med."},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib111","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/annonc\/mdy099","article-title":"RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer","volume":"29","author":"Cruz","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2025.118719_bib112","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib113","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-016-3026-2","article-title":"Lack of MRE11-RAD50-NBS1 (MRN) complex detection occurs frequently in low-grade epithelial ovarian cancer","volume":"17","author":"Brandt","year":"2017","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib114","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ygyno.2016.01.004","article-title":"Copy number deletion of RAD50 as predictive marker of BRCAness and PARP inhibitor response in BRCA wild type ovarian cancer","volume":"141","author":"Zhang","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib115","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1158\/0008-5472.CAN-19-1991","article-title":"Rare BRIP1 missense alleles confer risk for ovarian and breast cancer","volume":"80","author":"Moyer","year":"2020","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib116","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13058-018-0935-9","article-title":"BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer","volume":"20","author":"Weber-Lassalle","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib117","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1111\/jcmm.14133","article-title":"PARP inhibitors in ovarian cancer: sensitivity prediction and resistance mechanisms","volume":"23","author":"Jiang","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.biopha.2025.118719_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104434","article-title":"Clinical and molecular features of platinum resistance in ovarian cancer","volume":"201","author":"Miras","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib119","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1158\/2159-8290.CD-16-0860","article-title":"Targeting DNA Repair in Cancer: beyond PARP Inhibitors","volume":"7","author":"Brown","year":"2017","journal-title":"Cancer Discov."},{"issue":"6330","key":"10.1016\/j.biopha.2025.118719_bib120","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1126\/science.aam7344","article-title":"PARP inhibitors: synthetic lethality in the clinic","volume":"355","author":"Lord","year":"2017","journal-title":"Science"},{"issue":"10106","key":"10.1016\/j.biopha.2025.118719_bib121","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib122","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","article-title":"Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: results from the phase III ENGOT-OV16\/NOVA trial","volume":"159","author":"Mirza","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2025.118719_bib123","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.tcb.2022.04.010","article-title":"DNA single-strand break repair and human genetic disease","volume":"32","author":"Caldecott","year":"2022","journal-title":"Trends Cell Biol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib124","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1128\/MCB.18.6.3563","article-title":"XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage","volume":"18","author":"Masson","year":"1998","journal-title":"Mol. Cell Biol."},{"issue":"22","key":"10.1016\/j.biopha.2025.118719_bib125","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1093\/nar\/24.22.4387","article-title":"XRCC1 polypeptide interacts with DNA polymerase beta and possibly poly (ADP-ribose) polymerase, and DNA ligase III is a novel molecular 'nick-sensor' in vitro","volume":"24","author":"Caldecott","year":"1996","journal-title":"Nucleic Acids Res."},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib126","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.molcel.2015.10.013","article-title":"PARP-1 activation requires local unfolding of an autoinhibitory domain","volume":"60","author":"Dawicki-McKenna","year":"2015","journal-title":"Mol. Cell"},{"issue":"10","key":"10.1016\/j.biopha.2025.118719_bib127","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.biopha.2025.118719_bib128","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.60637","article-title":"PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response","volume":"9","author":"Kim","year":"2020","journal-title":"Elife"},{"issue":"8007","key":"10.1016\/j.biopha.2025.118719_bib129","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41586-024-07217-2","article-title":"Transcription-replication conflicts underlie sensitivity to PARP inhibitors","volume":"628","author":"Petropoulos","year":"2024","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biopha.2025.118719_bib130","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-18-0474","article-title":"Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids","volume":"8","author":"Hill","year":"2018","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib131","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2019.08.002","article-title":"Diverse mechanisms of PARP inhibitor resistance in ovarian cancer","volume":"1872","author":"Wakefield","year":"2019","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.biopha.2025.118719_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100744","article-title":"Overcoming PARPi resistance: preclinical and clinical evidence in ovarian cancer","volume":"55","author":"Chiappa","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib133","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1038\/s41467-021-22582-6","article-title":"Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)","volume":"12","author":"Swisher","year":"2021","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2025.118719_bib134","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1158\/2159-8290.CD-18-0715","article-title":"BRCA reversion mutations in circulating tumor DNA predict primary and acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"9","author":"Lin","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.biopha.2025.118719_bib135","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.3389\/fonc.2019.01289","article-title":"Genomic profile and BRCA-1 promoter methylation status in brca mutated ovarian cancer: new insights in predictive biomarkers of olaparib response","volume":"9","author":"Franzese","year":"2019","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib136","doi-asserted-by":"crossref","first-page":"3970","DOI":"10.1038\/s41467-018-05564-z","article-title":"Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma","volume":"9","author":"Kondrashova","year":"2018","journal-title":"Nat. Commun."},{"issue":"9","key":"10.1016\/j.biopha.2025.118719_bib137","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/2159-8290.CD-17-0419","article-title":"Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma","volume":"7","author":"Kondrashova","year":"2017","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib138","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1158\/1541-7786.MCR-17-0607","article-title":"Olaparib-induced adaptive response is disrupted by FOXM1 targeting that enhances sensitivity to PARP inhibition","volume":"16","author":"Fang","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib139","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s41467-019-09232-8","article-title":"The deubiquitylating enzyme USP15 regulates homologous recombination repair and cancer cell response to PARP inhibitors","volume":"10","author":"Peng","year":"2019","journal-title":"Nat. Commun."},{"issue":"42","key":"10.1016\/j.biopha.2025.118719_bib140","doi-asserted-by":"crossref","first-page":"17041","DOI":"10.1073\/pnas.1305170110","article-title":"Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance","volume":"110","author":"Johnson","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7716","key":"10.1016\/j.biopha.2025.118719_bib141","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41586-018-0340-7","article-title":"The shieldin complex mediates 53BP1-dependent DNA repair","volume":"560","author":"Noordermeer","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib142","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ygyno.2019.01.015","article-title":"53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer","volume":"153","author":"Hurley","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib143","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-12-0049","article-title":"Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors","volume":"3","author":"Jaspers","year":"2013","journal-title":"Cancer Discov."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib144","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ccell.2019.05.012","article-title":"Selective Loss of PARG Restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality","volume":"35","author":"Gogola","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2025.118719_bib145","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.dnarep.2017.02.010","article-title":"Specific killing of DNA damage-response deficient cells with inhibitors of poly(ADP-ribose) glycohydrolase","volume":"52","author":"Gravells","year":"2017","journal-title":"DNA Repair (Amst. )"},{"issue":"21","key":"10.1016\/j.biopha.2025.118719_bib146","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by Clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib147","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1038\/s41467-018-03917-2","article-title":"Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance","volume":"9","author":"Pettitt","year":"2018","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.biopha.2025.118719_bib148","doi-asserted-by":"crossref","first-page":"4516","DOI":"10.1158\/0008-5472.CAN-16-0416","article-title":"A radiotracer strategy to quantify PARP-1 expression in vivo provides a biomarker that can enable patient selection for PARP inhibitor therapy","volume":"76","author":"Makvandi","year":"2016","journal-title":"Cancer Res."},{"issue":"9","key":"10.1016\/j.biopha.2025.118719_bib149","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093233","article-title":"Mechanisms of multidrug resistance in cancer chemotherapy","volume":"21","author":"Bukowski","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib150","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2004.03.035","article-title":"RNA expression of MDR1\/P-glycoprotein, DNA-topoisomerase I, and MRP2 in ovarian carcinoma patients: correlation with chemotherapeutic response","volume":"94","author":"Materna","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"44","key":"10.1016\/j.biopha.2025.118719_bib151","doi-asserted-by":"crossref","first-page":"17079","DOI":"10.1073\/pnas.0806092105","article-title":"High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs","volume":"105","author":"Rottenberg","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib152","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Cancer"},{"issue":"7553","key":"10.1016\/j.biopha.2025.118719_bib153","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature14410","article-title":"Whole-genome characterization of chemoresistant ovarian cancer","volume":"521","author":"Patch","year":"2015","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib154","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat. Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib155","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","article-title":"PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation","volume":"9","author":"Ronson","year":"2018","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2025.118719_bib156","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cell.2011.03.041","article-title":"Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11","volume":"145","author":"Schlacher","year":"2011","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib157","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"Schlacher","year":"2012","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib158","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41580-020-0218-z","article-title":"The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication","volume":"21","author":"Tarsounas","year":"2020","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"7766","key":"10.1016\/j.biopha.2025.118719_bib159","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s41586-019-1363-4","article-title":"Isomerization of BRCA1-BARD1 promotes replication fork protection","volume":"571","author":"Daza-Martin","year":"2019","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.biopha.2025.118719_bib160","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J. Clin. Invest"},{"issue":"23","key":"10.1016\/j.biopha.2025.118719_bib161","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1158\/0008-5472.CAN-20-1439","article-title":"Targeting the PI3K\/mTOR pathway augments CHK1 inhibitor-induced replication stress and antitumor activity in high-grade serous ovarian cancer","volume":"80","author":"Huang","year":"2020","journal-title":"Cancer Res."},{"issue":"36","key":"10.1016\/j.biopha.2025.118719_bib162","doi-asserted-by":"crossref","first-page":"4354","DOI":"10.1200\/JCO.2016.67.5942","article-title":"Phase II study of WEE1 inhibitor AZD1775 Plus carboplatin in patients With TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months","volume":"34","author":"Leijen","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2025.118719_bib163","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s43018-021-00203-x","article-title":"A first-in-class polymerase theta inhibitor selectively targets homologous-recombination-deficient tumors","volume":"2","author":"Zhou","year":"2021","journal-title":"Nat. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2025.118719_bib164","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","article-title":"Targeting DNA damage response promotes antitumor immunity through STING-Mediated T-cell activation in small cell lung cancer","volume":"9","author":"Sen","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib165","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.molcel.2020.07.026","article-title":"DNA damage and cancer immunotherapy: a STING in the tale","volume":"80","author":"Reislander","year":"2020","journal-title":"Mol. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2025.118719_bib166","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13045-021-01218-8","article-title":"The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009138?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225009138?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T06:56:53Z","timestamp":1777013813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225009138"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":166,"alternative-id":["S0753332225009138"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118719","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DNA repair pathways in ovarian cancer: Implications for therapy and resistance","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118719","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118719"}}